PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDapagliflozin
Farxiga, Forxiga(dapagliflozin)
Dapagliflozin, Ebymect, Edistride, Farxiga, Forxiga, Qtern, Qternmet, Qtrilmet, Xigduo (dapagliflozin) is a small molecule pharmaceutical. Dapagliflozin was first approved as Forxiga on 2012-11-11. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat chronic renal insufficiency, diabetes mellitus, glucose metabolism disorders, heart failure, and metabolic diseases amongst others.
Download report
Favorite
COVID-19
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
cardiovascular diseasesD002318
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Dapagliflozin, Farxiga
Combinations
Dapagliflozin metformin, Dapagliflozin saxagliptin, Xigduo (discontinued: Qtern, Qternmet)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dapagliflozin
Tradename
Company
Number
Date
Products
FARXIGAAstraZenecaN-202293 RX2014-01-08
2 products, RLD, RS
Dapagliflozin
+
Saxagliptin hydrochloride
Tradename
Company
Number
Date
Products
QTERNAstraZenecaN-209091 DISCN2017-02-27
2 products, RLD
Hide discontinued
Dapagliflozin
+
Metformin hydrochloride
+
Saxagliptin hydrochloride
Tradename
Company
Number
Date
Products
QTERNMET XRAstraZenecaN-210874 DISCN2019-05-02
4 products, RLD
Hide discontinued
Dapagliflozin
+
Metformin hydrochloride
Tradename
Company
Number
Date
Products
XIGDUO XRAstraZenecaN-205649 RX2014-10-29
5 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
dapagliflozinANDA2026-07-17
dapagliflozin and metformin hydrochlorideANDA2026-06-11
dapagliflozin and saxagliptinANDA2026-04-08
farxigaNew Drug Application2026-07-10
xigduoNew Drug Application2024-12-20
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
heart failureEFO_0003144D006333I50
type 2 diabetes mellitusEFO_0001360D003924E11
Agency Specific
FDA
EMA
Expiration
Code
DAPAGLIFLOZIN, FARXIGA, ASTRAZENECA AB
2024-04-30I-857
2023-05-05I-834
Patent Expiration
Patent
Expires
Flag
FDA Information
Dapagliflozin, Farxiga, Astrazeneca Ab
109738362040-03-09U-3127
86859342030-05-26U-1522
87216152030-01-18DP
79195982029-12-16DP
78515022028-08-19DP
82217862028-03-21DP
83619722028-03-21U-493, U-1976, U-1977, U-2139
87162512028-03-21DP
85016982027-06-20DPU-493, U-1976, U-1977
83296482026-08-18U-2139, U-2212, U-2213
89068512026-08-18U-2139
65151172025-10-04DS, DPU-493, U-2139
74562542025-06-30DPU-2139
84316852025-04-13DPU-2139
84611052025-04-13DPU-2139
92380762024-04-15DPU-2139
Dapagliflozin / Metformin Hydrochloride, Xigduo Xr, Astrazeneca Ab
96160282030-11-12DP
Dapagliflozin / Metformin Hydrochloride / Saxagliptin Hydrochloride, Qternmet Xr, Astrazeneca Ab
86287992025-07-13DP
RE441862023-07-31DS, DPU-493
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BD: Combinations of oral blood glucose lowering drugs
— A10BD15: Metformin and dapagliflozin
— A10BD21: Saxagliptin and dapagliflozin
— A10BD25: Metformin, saxagliptin and dapagliflozin
— A10BK: Sodium-glucose co-transporter 2 (sglt2) inhibitors
— A10BK01: Dapagliflozin
HCPCS
No data
Clinical
Clinical Trials
756 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E1133228310359293
Diabetes mellitusD003920EFO_0000400E08-E131114566136172
Heart failureD006333EFO_0003144I50520253536114
Chronic renal insufficiencyD051436—N1842114141665
Kidney diseasesD007674EFO_0003086N0821612101147
Type 1 diabetes mellitusD003922EFO_0001359E10681011437
HypertensionD006973EFO_0000537I103374521
Myocardial infarctionD009203EFO_0000612I21—264718
Cardiovascular diseasesD002318EFO_0000319I98—138718
InfarctionD007238EFO_0009463——163615
Show 112 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Retinal diseasesD012164—H35.9—12—25
Polycystic ovary syndromeD011085EFO_0000660E28.2——4——4
Sleep apnea syndromesD012891EFO_0003877G47.3—11—13
StrokeD020521EFO_0000712I63.9—22——3
SepsisD018805EFO_0001420A41.9——1—23
Cognitive dysfunctionD060825—G31.84—11—23
Ischemic strokeD000083242———12—13
Endocrine system diseasesD004700EFO_0001379E34.9——3——3
AscitesD001201—R18—31——3
Catheter ablationD017115——111——2
Show 40 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver cirrhosisD008103EFO_0001422K74.0—3——14
NeoplasmsD009369—C8011——13
Pulmonary arterial hypertensionD000081029———1——12
EdemaD004487—R60.9—1——12
CystinuriaD003555—E72.01—2———2
Prostatic neoplasmsD011471—C6111———2
Triple negative breast neoplasmsD064726——11———2
Alcoholic fatty liverD005235—K70.0—1——12
AmyloidosisD000686EFO_1001875E85—1——12
DepressionD003863—F33.912———2
Show 29 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———28———129
Diabetic ketoacidosisD016883EFO_1000897—1———34
Lung neoplasmsD008175—C34.901———12
Pancreatic neoplasmsD010190EFO_0003860C251————1
Therapeutic equivalencyD013810——1————1
MalnutritionD044342EFO_0008572E40-E461————1
Reperfusion injuryD015427——1————1
Vascular ringD000073872—Q25.451————1
HyperinsulinismD006946—E16.11————1
HypothyroidismD007037EFO_0004705E03.91————1
Show 3 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Urinary tract infectionsD014552EFO_0003103N39.0————44
InfectionsD007239EFO_0000544—————33
HemorrhageD006470MP_0001914R58————11
Coronavirus infectionsD018352EFO_0007224B34.2————11
MenorrhagiaD008595EFO_0003945N92.0————11
Hemophilia aD006467EFO_0007267D66————11
PainD010146EFO_0003843R52————11
Down syndromeD004314EFO_0001064Q90————11
PneumoniaD011014EFO_0003106J18————11
Mucocutaneous lymph node syndromeD009080EFO_0004246M30.3————11
Show 34 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDapagliflozin
INNdapagliflozin
Description
Dapagliflozin is a C-glycosyl comprising beta-D-glucose in which the anomeric hydroxy group is replaced by a 4-chloro-3-(4-ethoxybenzyl)phenyl group. Used (in the formo f its propanediol monohydrate) to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes. It has a role as a hypoglycemic agent and a sodium-glucose transport protein subtype 2 inhibitor. It is a C-glycosyl compound, an organochlorine compound and an aromatic ether.
Classification
Small molecule
Drug classphlorozin derivatives, phenolic glycosides
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1
Identifiers
PDB—
CAS-ID461432-26-8
RxCUI—
ChEMBL IDCHEMBL429910
ChEBI ID85078
PubChem CID9887712
DrugBankDB06292
UNII ID1ULL0QJ8UC (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Qtern – AstraZeneca
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Farxiga – AstraZeneca
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Forxiga – Bristol Myers Squibb
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Dapagliflozin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
Black-box warning for: Dapagliflozin and metformin hydrochloride, Xigduo
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
50,290 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use